ArticleFrontiers in public health2026
MLP-CKD: a clinically informed deep learning framework for admission laboratory-based screening and risk stratification of uremia-associated advanced renal dysfunction.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a clinically informed deep learning framework for admission laboratory-based screening and risk stratification of uremia-associated advanced renal dysfunction. Methods: We propose MLP-CKD, a multi-branch feature interaction-enhanced multilayer perceptron that groups laboratory variables by clinical domain and incorporates missingness indicators to capture test-availability patterns. Adult ICU patients were extracted from MIMIC-IV, and laboratory measurements obtained within the first 24 h after ICU admission were summarized using mean, minimum, and maximum values. To prevent information leakage, only the first eligible ICU stay per patient was retained, and all model development was conducted using patient-level training, validation, and independent test splits. MLP-CKD was compared against conventional machine learning models, neural network ablation variants, and clinical rule-based baselines. Performance was assessed using discrimination, calibration, decision curve analysis, bootstrap-based 95% confidence intervals, and permutation importance. Results: On the independent patient-level test set, MLP-CKD achieved an AUC of 0.913 (95% CI: 0.907-0.919) and an AUPRC of 0.848 (95% CI: 0.838-0.859), representing the best discrimination among the primary models. Its recall and F1-score were 0.796 and 0.764, respectively. Ablation analysis showed that the Branch-only MLP achieved near-equivalent discrimination (AUC 0.913; paired-bootstrap Conclusion: MLP-CKD provides a clinically structured framework for admission laboratory-based screening and risk stratification of uremia-associated advanced renal dysfunction. The model achieved competitive discrimination and clinically plausible feature-importance patterns, with its main advantage arising from clinically informed feature grouping. Because this retrospective study used admission-window laboratory variables without a predefined future prediction horizon, MLP-CKD should be interpreted as a decision-support tool rather than as a standalone diagnostic system or a model for predicting disease onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.